Oramed to Present Poster on its Oral Insulin Capsule at the Yale Diabetes Symposium - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Oramed to Present Poster on its Oral Insulin Capsule at the Yale Diabetes Symposium


Oramed to Present Poster on its Oral Insulin Capsule at the Yale Diabetes Symposium

PR Newswire

JERUSALEM, May 13, 2014 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a poster on the Company's orally ingestible insulin capsule, ORMD-0801, will be presented at the Yale Diabetes Symposium on Wednesday, May 14, 2014.

Yale Diabetes Symposium      

Date: May 14, 2014

Presenter: Ehud Arbit, MD, Director of Research & Development, Oramed Pharmaceuticals

Poster Title: Oral Insulin Capsules: A Snapshot in Time

Location: Yale University West Campus, West Haven, CT

The poster will include data from previously announced clinical trials in type 1 and type 2 diabetes patients. The poster will be available on Oramed's website from the day of the symposium at http://oramed.com/index.php?page=13.

About the Yale Diabetes Symposium 

The Yale Diabetes Symposium is a Pan-Connecticut Symposium dedicated to "Innovative Approaches to Diabetes Research and Therapies," co-sponsored by Yale University and the University of Connecticut, in cooperation with The Jackson Laboratory, and in coordination with the Juvenile Diabetes Research Foundation International.    

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in separate Phase II clinical trials in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering IND-enabling studies later this year.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected design or timing thereof, the anticipated safety of ORMD-0801 and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Contacts: 

Oramed Pharmaceuticals
Aviva Guiloff
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: aviva@oramed.com 

LifeSci Advisors, LLC
Michael Rice
+1-646-597-6979
mrice@lifesciadvisors.com

SOURCE Oramed Pharmaceuticals Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here